A loss-of-function IFNAR1 allele in Polynesia underlies severe viral diseases in homozygotes.
Journal article
Bastard P. et al, (2022), J Exp Med, 219
Sero-prevalence of 19 infectious pathogens and associated factors among middle-aged and elderly Chinese adults: a cross-sectional study
Journal article
YAO P. et al, (2022), BMJ Open
Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study
Journal article
Närhi F. et al, (2022), The Lancet Digital Health, 4, e220 - e234
Vitamin D Deficiency and Its Association with Iron Deficiency in African Children.
Journal article
Mogire RM. et al, (2022), Nutrients, 14
Identification of host-pathogen-disease relationships using a scalable Multiplex Serology platform in UK Biobank
Journal article
MENTZER A. et al, (2022), Nature Communications
Divergent trajectories of antiviral memory after SARS-CoV-2 infection.
Journal article
Tomic A. et al, (2022), Nat Commun, 13
A blood atlas of COVID-19 defines hallmarks of disease severity and specificity
Journal article
Ahern DJ. et al, (2022), Cell, 185, 916 - 938.e58
Implementation and Extended Evaluation of the Euroimmun Anti-SARS-CoV-2 IgG Assay and Its Contribution to the United Kingdom's COVID-19 Public Health Response.
Journal article
Otter AD. et al, (2022), Microbiol Spectr, 10
Response to Letter to the Editor by Ish et al. entitled 'COVID-19 vaccine equity-the need of the hour'.
Journal article
Maclean P. et al, (2022), QJM
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.
Journal article
Dejnirattisai W. et al, (2022), Cell
Fitting to the UK COVID-19 outbreak, short-term forecasts and estimating the reproductive number
Journal article
Keeling MJ. et al, (2022), Statistical Methods in Medical Research
T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study
Journal article
Angyal A. et al, (2022), The Lancet Microbe, 3, e21 - e31
Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.
Dejnirattisai W. et al, (2021)
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Journal article
LANDRAY M. et al, (2021), The Lancet
Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial.
Journal article
Fisher BA. et al, (2021), Lancet Respir Med
Why do breakthrough COVID-19 infections occur in the vaccinated?
Journal article
Maclean P. et al, (2021), QJM
An immunodominant NP105-113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease.
Journal article
Peng Y. et al, (2021), Nat Immunol
The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants.
Journal article
Liu C. et al, (2021), Cell Host Microbe
Serum calprotectin is not an independent predictor of severe COVID-19 in ambulatory adult patients.
Journal article
Mentzer DAJ. et al, (2021), J Infect